536 related articles for article (PubMed ID: 18177218)
1. Antimicrobial-associated risk factors for Clostridium difficile infection.
Owens RC; Donskey CJ; Gaynes RP; Loo VG; Muto CA
Clin Infect Dis; 2008 Jan; 46 Suppl 1():S19-31. PubMed ID: 18177218
[TBL] [Abstract][Full Text] [Related]
2. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain.
O'Connor JR; Johnson S; Gerding DN
Gastroenterology; 2009 May; 136(6):1913-24. PubMed ID: 19457419
[TBL] [Abstract][Full Text] [Related]
3. What is the role of antimicrobial resistance in the new epidemic of Clostridium difficile?
Coia JE
Int J Antimicrob Agents; 2009 Mar; 33 Suppl 1():S9-12. PubMed ID: 19303572
[TBL] [Abstract][Full Text] [Related]
4. Measures to control and prevent Clostridium difficile infection.
Gerding DN; Muto CA; Owens RC
Clin Infect Dis; 2008 Jan; 46 Suppl 1():S43-9. PubMed ID: 18177221
[TBL] [Abstract][Full Text] [Related]
5. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
Adams DA; Riggs MM; Donskey CJ
Antimicrob Agents Chemother; 2007 Aug; 51(8):2674-8. PubMed ID: 17562807
[TBL] [Abstract][Full Text] [Related]
6. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model.
Baines SD; Freeman J; Wilcox MH
J Antimicrob Chemother; 2005 Jun; 55(6):974-82. PubMed ID: 15860551
[TBL] [Abstract][Full Text] [Related]
7. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.
Baines SD; Saxton K; Freeman J; Wilcox MH
J Antimicrob Chemother; 2006 Nov; 58(5):1062-5. PubMed ID: 17030519
[TBL] [Abstract][Full Text] [Related]
8. Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors.
Debast SB; Vaessen N; Choudry A; Wiegers-Ligtvoet EA; van den Berg RJ; Kuijper EJ
Clin Microbiol Infect; 2009 May; 15(5):427-34. PubMed ID: 19416295
[TBL] [Abstract][Full Text] [Related]
9. Incidence of Clostridium difficile infections in patients receiving antimicrobial and acid-suppression therapy.
King RN; Lager SL
Pharmacotherapy; 2011 Jul; 31(7):642-8. PubMed ID: 21923450
[TBL] [Abstract][Full Text] [Related]
10. Implications of the changing face of Clostridium difficile disease for health care practitioners.
McFarland LV; Beneda HW; Clarridge JE; Raugi GJ
Am J Infect Control; 2007 May; 35(4):237-53. PubMed ID: 17482995
[TBL] [Abstract][Full Text] [Related]
11. What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea?
Blondeau JM
J Antimicrob Chemother; 2009 Feb; 63(2):238-42. PubMed ID: 19028718
[TBL] [Abstract][Full Text] [Related]
12. A case-control study of community-associated Clostridium difficile infection.
Wilcox MH; Mooney L; Bendall R; Settle CD; Fawley WN
J Antimicrob Chemother; 2008 Aug; 62(2):388-96. PubMed ID: 18434341
[TBL] [Abstract][Full Text] [Related]
13. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents.
Riggs MM; Sethi AK; Zabarsky TF; Eckstein EC; Jump RL; Donskey CJ
Clin Infect Dis; 2007 Oct; 45(8):992-8. PubMed ID: 17879913
[TBL] [Abstract][Full Text] [Related]
14. Clostridium difficile-associated diarrhoea.
Elliott B; Chang BJ; Golledge CL; Riley TV
Intern Med J; 2007 Aug; 37(8):561-8. PubMed ID: 17640189
[TBL] [Abstract][Full Text] [Related]
15. Fluoroquinolone and Macrolide Exposure Predict Clostridium difficile Infection with the Highly Fluoroquinolone- and Macrolide-Resistant Epidemic C. difficile Strain BI/NAP1/027.
Wieczorkiewicz JT; Lopansri BK; Cheknis A; Osmolski JR; Hecht DW; Gerding DN; Johnson S
Antimicrob Agents Chemother; 2016 Jan; 60(1):418-23. PubMed ID: 26525793
[TBL] [Abstract][Full Text] [Related]
16. Evidence for low risk of Clostridium difficile infection associated with tigecycline.
Wilcox MH
Clin Microbiol Infect; 2007 Oct; 13(10):949-52. PubMed ID: 17697004
[TBL] [Abstract][Full Text] [Related]
17. Update on Clostridium difficile infection.
O'Donoghue C; Kyne L
Curr Opin Gastroenterol; 2011 Jan; 27(1):38-47. PubMed ID: 21099432
[TBL] [Abstract][Full Text] [Related]
18. Management of Clostridium difficile infection: thinking inside and outside the box.
Gerding DN; Johnson S
Clin Infect Dis; 2010 Dec; 51(11):1306-13. PubMed ID: 20979491
[TBL] [Abstract][Full Text] [Related]
19. Clostridium difficile and fluoroquinolones: is there a link?
Weiss K
Int J Antimicrob Agents; 2009 Mar; 33 Suppl 1():S29-32. PubMed ID: 19303566
[TBL] [Abstract][Full Text] [Related]
20. A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics.
Garey KW; Dao-Tran TK; Jiang ZD; Price MP; Gentry LO; Dupont HL
J Hosp Infect; 2008 Oct; 70(2):142-7. PubMed ID: 18723249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
